AAN Summer Conference Exhibit and On-site Guide

July 15–16, San Francisco and Virtual

Autoimmune Neurology and Neurology Year in Review EXHIBIT AND ON-SITE GUIDE AAN.com/SummerConference • #AANSC

WHAT’S INSIDE Meeting Tips..................................................................... 1 Schedule........................................................................... 3 Posters............................................................................. 13 Exhibit Hall Map................................................................ 26 Exhibitor Listing................................................................ 27 COVID-19 Protocols and Select Meeting Policies.............. 34

MEETING TIPS Quick Links For handy access to most of the links mentioned below and to download your certificate of attendance, visit AAN.com/SCQuickLinks.

WiFi WiFi is available throughout the conference:

Network: AANSC Password: autoimmune

Program Materials Available online at AAN.com/materials. Use your six-digit AAN ID and password to log in. Please note that availability of materials is at the discretion of the specific speaker. Not all sessions will have materials.

CME

Claiming CME Credits CME hours can be claimed by completing the program evaluation at AAN.com/view/CME by August 15, 2022, with Full Registration or by May 30, 2023, with Gold Registration. Transcripts will be available upon evaluation submission. AAN members can also access their transcript via NeuroTracker™ at AAN.com/view/NeuroTracker.

Meals Your registration includes coffee breaks and lunch daily, and food and beverages at the Exhibit Hall Opening Reception. Times and locations are noted in the schedule. Attendees who booked within the AAN hotel block received at hotel check-in up to two vouchers to be used toward breakfast in the Pantry or B55 on the lobby level of the San Francisco Marriott Marquis on conference days.

AAN.com/SCQuickLinks

1

MEETING TIPS Livestreaming & Session Recording Visit AAN.com/VirtualSC and log in with your six-digit AAN ID and password to livestream sessions. This option works best using Google Chrome on a desktop or tablet. Session recordings will be available in the virtual platform’s AAN Rewind auditorium approximately 24 hours after their originally scheduled time at the same URL. You can access session recordings through August 15, 2022, with your registration. If you upgraded to Gold Registration, you’ll have access to session recordings in the Online Learning Center (learning.aan.com) from August 16, 2022 - May 30, 2023.

Want to extend your access? Visit the registration desk or email aanscsupport@cmrus.com by August 15, 2022.

Family Room A private nursing/pumping room is available for use during the conference. To use, please check in at the registration desk.

Exhibit Hall Learn about the latest advancements in products and services enhancing the lives of autoimmune neurology patients and their care providers.

Use your Exhibit Hall passport to visit a world of exhibitors and enter drawings to win prizes including Bose Noise Cancelling Headphones and 2022 AAN Fall Conference Registration.

Join us for the Exhibit Hall Opening Reception sponsored by Genentech, a Member of the Roche Group, on Friday, July 15, from 3:30 p.m.–4:45 p.m., which will offer attendees an opportunity to enjoy refreshments, network with new and known colleagues, and visit exhibits.

2 #AANSC

SCHEDULE

FRIDAY, JULY 15

8:00 a.m. –11:40 a.m.

C1: Autoimmune Neurology General Session Location: Yerba Buena Salon 9

CME

3.25

Learning Objectives: Participants should get an update on novel antibody biomarkers and comprehend the clinical trial design challenges and recent trial results in autoimmune neurology.

Lecture/Faculty:

11:40 a.m. –1:00 p.m.

FRIDAY, JULY 15

8:00 a.m.–8:10 a.m. » Welcome/Introduction Stacey Clardy, MD, PhD, FAAN, Salt Lake City, UT Anastasia Zekeridou, MD, PhD, Rochester, MN 8:10 a.m.–8:55 a.m. » NMDA Receptor Encephalitis: From Discovery Through Pathophysiology to Therapeutics Josep O. Dalmau, MD, PhD, FAAN, Barcelona, Spain 8:55 a.m.–9:00 a.m. » Questions and Answers Josep O. Dalmau, MD, PhD, FAAN, Barcelona, Spain 9:00 a.m.–9:25 a.m. » Neuromyelitis Optica Spectrum Disorders: From Bench to FDA Approvals, Lessons Learned Sean J. Pittock, MD, Rochester, MN 9:25 a.m.–9:30 a.m. » Questions and Answers Sean J. Pittock, MD, Rochester, MN 9:30 a.m.–9:55 a.m. » Autoimmune Encephalitis: Ongoing Trials and Challenges Ahead Maarten Jan Titulaer, MD, PhD, Rotterdam, Netherlands 9:55 a.m.–10:00 a.m. » Questions and Answers Maarten Jan Titulaer, MD, PhD, Rottterdam, Netherlands 10:00 a.m.–10:25 a.m. » What Next? Strategically Targeting Future Trials in Rare Neurologic Diseases David B. Clifford, MD, FAAN, Saint Louis, MO

10:25 a.m.–10:30 a.m. » Questions and Answers David B. Clifford, MD, FAAN, Saint Louis, MO 10:30 a.m.–10:40 a.m. » Break 10:40 a.m.–11:05 a.m. » Neural Autoantibodies Targeting Synapses Francesc R. Graus, MD, Barcelona, Spain 11:05 a.m.–11:10 a.m. » Questions and Answers Francesc R. Graus, MD, Barcelona, Spain 11:10 a.m.–11:35 a.m. » Neural Autoantibodies Specific for Intracellular Proteins Andrew McKeon, MD, Rochester, MN 11:35 a.m.–11:40 a.m. » Questions and Answers Andrew McKeon, MD, Rochester, MN

Poster Session 1, Exhibit Hall, and Lunch Location: Yerba Buena Salons 7-8

AAN.com/SCQuickLinks

3

SCHEDULE

FRIDAY, JULY 15

1:00 p.m. –3:45 p.m.

C2 : Neurology Year in Review Location: Yerba Buena Salon 9

3:30 p.m. –4:45 p.m.

CME

2.75

Learning Objectives: This session looks back at the past year, highlighting some of the most relevant strides made in neurology subspecialties.

Exhibit Hall Opening Reception and Poster Session 1 Location: Yerba Buena Salons 7-8 Exhibit Hall Opening Reception is sponsored by

FRIDAY, JULY 15

Lecture/Faculty: 1:00 p.m.–1:25 p.m. » Headache Teshamae Monteith, MD, FAAN, Miami, FL 1:25 p.m.–1:50 p.m. » Multiple Sclerosis Robert T. Naismith, MD, FAAN, Saint Louis, MO 1:50 p.m.–2:15 p.m. » Epilepsy Maria J. Bruzzone, MD, Gainesville, FL 2:15 p.m.–2:40 p.m. » Dementia Gil Dan Rabinovici, MD, FAAN, San Francisco, CA 2:40 p.m.–3:05 p.m. » Movement Disorders Ian O. Bledsoe, MD, San Francisco, CA 3:05 p.m.–3:30 p.m. » Cerebrovascular Disease David L. Tirschwell, MD, FAAN, Seattle, WA 3:30 p.m.–3:45 p.m. » Panel Discussion Nicole Beaton Sur, MD, Miami, FL Teshamae Monteith, MD, FAAN, Miami, FL Gil Dan Rabinovici, MD, FAAN, San Francisco, CA Robert T. Naismith, MD, FAAN, Saint Louis, MO Maria J. Bruzzone, MD, Gainesville, FL David L. Tirschwell, MD, FAAN, Seattle, WA Ian O. Bledsoe, MD, San Francisco, CA

4:45 p.m. –6:30 p.m.

C3: Autoimmune Neurology Case Studies Location: Yerba Buena Salon 9

CME

1.75

Learning Objectives: Participants should become familiar with recognizing and diagnosing neurologic autoimmunity, interpret diagnostic testing, recognize pitfalls and avoid misdiagnosis, and manage and treat neurologic autoimmune disorders.

Lecture/Faculty: 4:45 p.m.–6:30 p.m. » Case Studies Stacey Clardy, MD, PhD, FAAN, Salt Lake City, UT Anastasia Zekeridou, MD, PhD, Rochester, MN Sean J. Pittock, MD, Rochester, MN Avindra Nath, MD, MBBS, FAAN, Bethesda, MD

The American Academy of Neurology would like to thank Kronus, Inc. for their support of the 2022 AAN Summer Conference: Autoimmune Neurology and Neurology Year in Review.

4 #AANSC

Information is accurate as of June 14, 2022, and is subject to change.

SATURDAY, JULY 16 6:30 a.m. –7:45 a.m.

Industry Therapeutic Update from argenx: Innovation in Anti-AChR Antibody Positive gMG Treatment for Adults: Clinical Data of VYVGART® in the Pivotal ADAPT Trial Location: Yerba Buena Salons 4-5

VYVGART is a human IgG1-derived Fc fragment that blocks FcRn and prevents IgG recycling, resulting in a reduction of circulating IgG, including levels of pathogenic autoantibodies that impair neuromuscular transmission in adult patients with gMG who are anti-AChR antibody positive. Join us and get your questions about VYVGART answered by our distinguished speakers.

C4: Neurologic Manifestations of Rheumatologic Disease Location: Nob Hill

CME

1.5

Learning Objectives: Participants should become familiar with recognizing and managing neurologic presentations of systemic autoimmunity.

Lecture/Faculty: 8:00 a.m.–8:27 a.m. » Neurosarcoidosis Jeffrey Marc Gelfand, MD, MAS, FAAN, San Francisco, CA 8:27 a.m.–8:54 a.m. » CNS Vasculitis: Primary vs. Secondary Rula Hajj-Ali, MD, Cleveland, OH 8:54 a.m.–9:20 a.m. » Other Neurologic Manifestations of Systemic Autoimmunity Amanda Lee Piquet, MD, Aurora, CO 9:20 a.m.–9:25 a.m. » Ischemic Stroke in Neurosarcoidosis: A Retrospective Cohort Analysis Spencer Hutto, MD, Atlanta, GA 9:25 a.m.–9:30 a.m. » Pachymeningitis in Biopsy-proven Sarcoidosis: Clinical Course, Radiographic Findings, Response to Treatment, and Longterm Outcomes Pressley A. Chakales, MD, Decatur, GA

Please note that no CME will be given by any accredited organization for attending.

Additionally, Industry Therapeutic Updates program content and the views expressed herein are those of the presenting corporate entity and not of the AAN. These programs are not an official part of the 2022 AAN Summer Conference education or scientific programs, nor are they endorsed by the AAN. The AAN cannot affirm claims pertaining to FDA off-label medication, research use of pre-FDA drugs, or other research information that might be discussed. Industry Therapeutic Updates are industry events.

AAN.com/SCQuickLinks

5

SATURDAY, JULY 16

Join us for breakfast as we discuss the phase 3 pivotal trial data for FDA-approved VYVGART® (efgartigimod alfa-fcab). VYVGART offers a unique mechanism of action for treating antiAChR antibody positive generalized myasthenia gravis (gMG) in adults. gMG is a rare but debilitating disease, whereby pathogenic immunoglobulin G (IgG) autoantibodies cause failure of signal transmission at the neuromuscular junction. The neonatal Fc receptor (FcRn) is a molecule that recycles IgG antibodies, including pathogenic autoantibodies, rescuing them from lysosomal degradation and perpetuating the underlying pathophysiology behind gMG.

8:00 a.m. –9:30 a.m.

SCHEDULE

SATURDAY, JULY 16

8:00 a.m. –9:30 a.m.

C5: Paraneoplastic Neurologic Syndromes and Neurologic Complications of Immune Checkpoint Inhibitor Cancer Immunotherapy

8:00 a.m. –9:30 a.m.

CME

1.5

Encephalitis/Epilepsy 1

CME

1.5

Location: Yerba Buena Salons 13-15

Learning Objectives: Participants should become familiar with clinical presentation and management of paraneoplastic neurologic diseases and neurologic immune related adverse events secondary to immune checkpoint inhibitor cancer immunotherapy.

Learning Objectives: Faculty will focus on the finer points of a diagnostic approach to autoimmune and infectious encephalitis, including some illustrative examples of misdiagnoses and how to avoid such pitfalls.

Participants should understand the evaluation of rapidly progressive dementias, including a focus on extracting encephalitis diagnoses from this broad category of disease.

Lecture/Faculty:

Lecture/Faculty:

Location: Yerba Buena Salons 10-12

SATURDAY, JULY 16

C6: Approach to Autoimmune

8:00 a.m.–8:27 a.m. » Paraneoplastic Neurologic Syndromes Divyanshu Dubey, MD, Rochester, MN 8:27 a.m.–8:54 a.m. » Neuromuscular Complications of Immune Checkpoint Inhibitor Cancer Immunotherapy Amanda C. Guidon, MD, Boston, MA 8:54 a.m.–9:20 a.m. » CNS Complications of Immune Checkpoint Inhibitor Cancer Immunotherapy Jerome Honnorat, MD, PhD, Lyon, France 9:20 a.m.–9:25 a.m. » Neuronal Uptake of Paraneoplastic and Other IgGs is Mediated by the Fc Portion of the IgG Molecule and Involves Previously Uncharacterized Neuronal FcγRI Receptors: Implications for Antibody-Mediated Neuronal Injury Tammy L. Smith, MD, PhD, Salt Lake City, UT 9:25 a.m. - 9:30 a.m. » Predictors for the Development of Neurological Immune-related Adverse Events of Immune Checkpoint Inhibitors and Impact on Mortality Chen Yan, MD, Medina, OH

8:00 a.m.–8:27 a.m. » Diagnostic Approach: Encephalitis Arun Venkatesan, MD, PhD, Baltimore, MD 8:27 a.m.–8:54 a.m. » (Mis)diagnosis of Rapidly Progressive Dementias Gregory S. Day, MD, MSc, FAAN, Jacksonville, FL 8:54 a.m.–9:20 a.m. » Pitfalls in Autoimmune Encephalitis: Cases Avindra Nath, MD, MBBS, FAAN, Bethesda, MD 9:20 a.m.–9:25 a.m. » Active Immunization Against NMDA NR1 Subunit as a Model of Autoimmune Encephalitis Jenny Linnoila, MD, PhD, Boston, MA 9:25 a.m.–9:30 a.m. » GABABR IgG Associated Encephalitis: Clinical Presentations and Measures to Improve Diagnostic Assay Specificity Jennifer McCombe, MD, Edmonton, AB, Canada

9:30 a.m. –10:00 a.m.

Poster Session 2 and Exhibit Hall Break Location: Yerba Buena Salons 7-8

6 #AANSC

Information is accurate as of June 14, 2022, and is subject to change.

SATURDAY, JULY 16 10:00 a.m. –11:30 a.m.

C7: Inflammatory Myopathies

and Autoimmune Neuromuscular Junction Disorders

10:00 a.m. –11:30 a.m.

CME

1.5

Location: Nob Hill Learning Objectives: Participants should be able to recognize, diagnose, and manage inflammatory myopathies and autoimmune neuromuscular junction disorders.

Lecture/Faculty:

Encephalitis/Epilepsy 2

CME

1.5

Location: Yerba Buena Salons 13-15 Learning Objectives: Faculty will emphasize encephalitis in the context of immune-mediated seizures, including FIRES and NORSE, as well as antibody-mediated epilepsy. Treatment approaches to autoimmune encephalitis will all be discussed in detail.

Lecture/Faculty: 10:00 a.m.–10:27 a.m. » FIRES and NORSE Krista L. Eschbach, MD, Aurora, CO 10:27 a.m.–10:54 a.m. » Antibody-mediated Epilepsy Sarosh Irani, MD, PhD, Oxford, United Kingdom 10:54 a.m.–11:20 a.m. » Treatment Approach to Autoimmune Encephalitis Amy Kunchok, MBBS, Cleveland, OH 11:20 a.m.–11:25 a.m. » Autoimmune Encephalitis Misdiagnosis in Adults; a Multicenter Observational Study of Outpatient Subspecialty Clinics Michael D. Geschwind, MD, PhD, FAAN, San Francisco, CA 11:25 a.m.–11:30 a.m. » Expanding Our Knowledge of the Immunogenetic Characteristics of AntiLGI1 Encephalitis – A Study of an Israeli Cohort Suggests Additional Significant HLA Associations with DQ Alleles Yahel Segal, MD, Tel-Aviv, Israel

AAN.com/SCQuickLinks

SATURDAY, JULY 16

10:00 a.m.–10:27 a.m. » Approach to Inflammatory Myopathies: Diagnostic Testing and Mimics Andrew Mammen, MD, PhD, Bethesda, MD 10:27 a.m.–10:54 a.m. » Inflammatory Myopathies: Clinical Findings and Treatment Suur Biliciler, MD, Houston, TX 10:54 a.m.–11:20 a.m. » Neuromuscular Junction Disorders: Approach to Diagnosis and Treatment of Myasthenia Gravis Neelam Goyal, MD, Palo Alto, CA 11:20 a.m. - 11:25 a.m. » Caveolae-Associated Protein (cavin)-4 Autoantibodies in Immune Mediated Rippling Muscle Disease M Bakri Hammami, MD, Bronx, NY 11:25 a.m.–11:30 a.m. » Comparison of Fixed Cell-based Assay to Radioimmunoprecipitation Assay for Acetylcholine Receptor Antibody Detection in Myasthenia Gravis Ario Mirian, MD, London, ON, Canada

C8: Approach to Autoimmune

7

SCHEDULE

SATURDAY, JULY 16

10:00 a.m. –11:30 a.m.

C9 : Autoimmune Movement Disorders

1:00 p.m. –2:30 p.m.

CME

1.5

Location: Yerba Buena Salons 10-12 Learning Objectives: This course will focus on the challenges associated with diagnosing an immune-mediated etiology and/ or component of movement disorders, with a specific focus on stiff person spectrum disorder (SPS). Specific to SPS, faculty will discuss systemic autoimmunity associated with SPS, as well as the clinical spectrum of conditions enveloped by the term “stiff person spectrum disease.” Finally, faculty will review treatment approaches in these hard-to-treat conditions.

SATURDAY, JULY 16

Lecture/Faculty: 10:00 a.m.–10:27 a.m. » Autoimmune Movement Disorders and Diagnostic Challenges Bettina Balint, MD, Zurich, Switzerland 10:27 a.m.–10:54 a.m. » Clinical Spectrum of Stiff-person Syndrome Scott Douglas Newsome, DO, FAAN, Baltimore, MD 10:54 a.m.–11:20 a.m. » Treatment of Stiff-person Syndrome Marinos C. Dalakas, MD, FAAN, Philadelphia, PA 11:20 a.m. - 11:25 a.m. » Therapeutic Plasma Exchange in the Management of Stiff Person Syndrome Spectrum Disorders: A Case Series and Review of the Literature Shuvro Roy, MD, Los Angeles, CA 11:25 a.m.–11:30 a.m. » Stiff Person Syndrome Misdiagnosis: Clinical and Ancillary Testing Characteristics Nicholas H. Chia, MBBS, Rochester, MN

C10 : Immune-mediated

Neuropathies

CME

1.5

Location: Yerba Buena Salons 10-12 Learning Objectives: Participants should become familiar with diagnostic approach to immune-mediated neuropathies and dysautonomia and the pitfalls of neural antibody testing.

Lecture/Faculty: 1:00 p.m.–1:27 p.m. » Antibody Testing in Immune-mediated Neuropathies Eric Lancaster, MD, PhD, Philadelphia, PA 1:27 p.m.–1:54 p.m. » Diagnostic Approach in Immune-mediated Neuropathies Annabel K. Wang, MD, FAAN, Long Beach, CA 1:54 p.m.–2:20 p.m. » Autoimmune Dysautonomia Steven Vernino, MD, PhD, FAAN, Dallas, TX 2:20 p.m.–2:25 p.m. » Characterization of Clinical and Paraclinical Features Associated with TS-HDS Autoantibody Seropositivity Mohamed Mostafa Rezk, MD, Rochester, MN 2:25 p.m.–2:30 p.m. » “Trigeminal Tract Sign” in Patients with Herpes Zoster Ophthalmicus: A Case Series of a Novel Imaging Finding Heather Yun Fei Yong, MD, Calgary, AB, Canada

11:30 a.m. –1:00 p.m.

Poster Session 2, Exhibit Hall, and Lunch Location: Yerba Buena Salons 7-8

8 #AANSC

Information is accurate as of June 14, 2022, and is subject to change.

SATURDAY, JULY 16 1:00 p.m. –2:30 p.m.

C11: Genetics in Autoinflammatory

Diseases

1:00 p.m. –2:30 p.m.

CME

1.5

Location: Yerba Buena Salons 13-15 Learning Objectives: Participants should become familiar with diagnostic approaches for genetic autoinflammatory syndromes and mimics.

Lecture/Faculty:

Inflammatory Myelopathies

CME

1.5

Location: Nob Hill Learning Objectives: The diagnosis of myelopathy can present a challenge for all clinicians, specifically elucidating the etiology and differentiating myelitis from all-cause myelopathy. Diagnostic considerations will be highlighted, as well as disease mimics. Further discussion will focus on the epidemiology of myelopathy and myelitis, as well as clinical outcomes.

Lecture/Faculty: 1:00 p.m.–1:27 p.m. » Transverse Myelitis Diagnosis and Diagnostic Criteria Benjamin M. Greenberg, MD, FAAN, Dallas, TX 1:27 p.m.–1:54 p.m. » Mimics of Autoimmune Myelopathies Alfonso Sebastian Lopez, MD, Jacksonville, FL 1:54 p.m.–2:20 p.m. » Epidemiology and Outcomes of Inflammatory Myelopathies Carlos A. Pardo-Villamizar, MD, Baltimore, MD 2:20 p.m.–2:25 p.m. » Characterization of Neurosarcoid Myelitis and Assessment of Treatment Response: A Multicenter Retrospective Study Denis Tan Kerim Balaban, MD, Brookline, MA 2:25 p.m.–2:30 p.m. » Spinal Central Canal Dilation in MOG Antibody-associated Disease Versus Other CNS Demyelinating Disorders Lauren Michelle Webb, MD, Rochester, MN

2:30 p.m. –3:00 p.m.

Poster Session 2 and Exhibit Hall Break Location: Yerba Buena Salons 7-8

AAN.com/SCQuickLinks

9

SATURDAY, JULY 16

1:00 p.m.–1:27 p.m. » Genetic Autoinflammatory Syndromes Ariane Soldatos, MD, FAAN, Bethesda, MD 1:27 p.m.–1:54 p.m. » Lymphocytic, Histiocytic, and Other Inflammatory Mimics W. Oliver Tobin, MB BCh, BAO, PhD, Rochester, MN 1:54 p.m.–2:20 p.m. » Practical Approach to Genetic Testing in Autoimmune Neurology Camilo Toro, MD, FAAN, Bethesda, MD 2:20 p.m.–2:25 p.m. » Genetics of Anti-NMDAR Encephalitis Sara Lomba, San Francisco, CA 2:25 p.m.–2:30 p.m. » Recurrent Acute Necrotizing Encephalopathy with Underlying RANBP2 Mutation Dhanalakshmi Angappan, MD, Beavearton, OR

C12 : Autoimmune and

SCHEDULE

SATURDAY, JULY 16

3:00 p.m. –4:30 p.m.

C13: Immunotherapy

3:00 p.m. –4:30 p.m.

CME

Considerations in Special Populations with Autoimmune Neurologic Conditions

1.5

Location: Yerba Buena Salons 10-12 Learning Objectives: Participants should become familiar with the challenges of immunotherapy in special populations including children, pregnant women, and elderly patients and how to navigate through these challenges.

In addition, they should become familiar with the immunodeficiencies resulting from the use of immunotherapies and how to monitor and treat these patients.

SATURDAY, JULY 16

Lecture/Faculty: 3:00 p.m.–3:27 p.m. » Immunotherapy During Pregnancy Riley Bove, MD, San Francisco, CA 3:27 p.m.–3:54 p.m. » Immunotherapy in Children E. Ann Yeh, MD, Toronto, ON, Canada 3:54 p.m.–4:20 p.m. » Immunotherapy in Patients with Primary or Acquired Immunodeficiencies Jennifer McCombe, MD, Edmonton, AB, Canada 4:20 p.m.–4:25 p.m. » Progressive Multifocal Leukoencephalopathy Associated With Sarcoidosis: A Multi-center Case Series Caleb Richard Schatz McEntire, MD, Boston, MA 4:25 p.m.–4:30 p.m. » Refractory Pediatric NMDA Receptor Encephalitis: A Case Series Varun Kannan, MD, Houston, TX

10 #AANSC

C14: Neuromyelitis Optica and

MOG-IgG Associated Disease

CME

1.5

Location: Nob Hill Learning Objectives: The last ten years has seen the development of consensus criteria for NMOSD and 3 FDA-approved treatments, while MOGAD diagnostic criteria are less well defined and there are no FDA approved treatments for MOGAD. Faculty will discuss each disorder in detail, as well as diagnostic challenges and disease mimics. Medication choice and other aspects of treatment will also be discussed, including both on and off label approaches (MOGAD has no approved medications), reflecting current real-world practice and challenges.

Lecture/Faculty: 3:00 p.m.–3:27 p.m. » NMO Clinical Manifestations and Diagnosis Dean M. Wingerchuk, MD, FAAN, Scottsdale, AZ 3:27 p.m.–3:54 p.m. » MOGAD Manifestations and Diagnosis Brenda Banwell, MD, FAAN, Philadelphia, PA 3:54 p.m.–4:20 p.m. » Practical Approach to Treatment Duriel Isaiah Hardy, MD, Austin, TX 4:20 p.m.–4:25 p.m. » Development of New or Enlarging MRI Lesions Outside of Clinical Attacks in MOGAntibody-associated Disease Stephanie Bridget Syc-Mazurek, MD, PhD, Rochester, MN 4:25 p.m.–4:30 p.m. » A Phase 3 Efficacy and Safety Study of Ravulizumab in Adult Patients with Neuromyelitis Optica Spectrum Disorder: Study Design and Methodology Sean J. Pittock, MD, Rochester, MN

Information is accurate as of June 14, 2022, and is subject to change.

SATURDAY, JULY 16 3:00 p.m. –4:30 p.m.

C15: Unusual Presentations of

CME

1.5

Neurologic Autoimmunity

Location: Yerba Buena Salons 13-15 Learning Objectives: Participants should become familiar with unusual presentations of neurologic autoimmunity that include sleep manifestations and ophthalmological manifestations or that happen in a postinfectious context.

Lecture/Faculty:

SATURDAY, JULY 16

3:00 p.m.–3:27 p.m. » Neuro-ophthalmological Manifestations of Neurologic Autoimmunity Lynn Gordon, MD, PhD, Tarzana, CA 3:27 p.m.–3:54 p.m. » Sleep in Autoimmune Encephalitis Joan Santamaria, MD, Barcelona, Spain 3:54 p.m.–4:20 p.m. » Post-infectious Neurologic Autoimmunity Michel Toledano, MD, Rochester, MN 4:20 p.m.–4:25 p.m. » Rank Wise Effect of HLA-DQ5 Explains Risk for the Development of Anti-IgLON5 Disease Selina Yogeshwar, MSc, Palo Alto, CA 4:25 p.m.–4:30 p.m. » Primary Immune Dysregulation in Subacute Sclerosing Panencephalitis: A Case-Control Study Vinay Suresh, Lucknow, Uttarpradesh, India

4:30 p.m. –5:00 p.m.

C16: Closing Keynote Location: Yerba Buena Salon 9

CME

0.5

Learning Objectives: To conclude the Summer Conference, faculty will review and celebrate the origins of what we currently consider to be the field of “autoimmune neurology,” including a focus on the pivotal scientific discoveries and clinical milestones that allowed for the growth of dedicated clinical endeavors.

Lecture/Faculty: 4:30 p.m.–5:00 p.m. » History of Autoimmune Neurology Vanda A. Lennon, MD, PhD, Rochester, MN AAN.com/SCQuickLinks

11

Come visit us at booth# 6

Providing actionable insights with

advanced neuroimmunology testing Autoimmune encephalitis

Paraneoplastic neurological syndromes (PNS)

Neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein (MOG) antibody disease

Neuroimmunological diseases are complex.

Testing for them shouldn’t be.

Myasthenia gravis

Multiple sclerosis Peripheral neuropathy

Learn more at QuestDiagnostics.com/Neuroimmunology © 2022 Quest Diagnostics Incorporated. All rights reserved. 6/2022

POSTERS

There will be two poster sessions—one on Friday, July 15, and one on Saturday, July 16—with distinct posters during each session. The Poster Hall is open: Friday, July 15: 11:40 a.m.–1:00 p.m.

3:30 p.m.–4:45 p.m.

Saturday, July 16: 9:30 a.m.–10:00 a.m.

11:30 a.m.–1:00 p.m.

2:30 p.m.–3:00 p.m.

Autoimmune Neurology Poster No.

Title

P1.1

The Prevalence and Clinical Phenotype of Dual Positive Neuromyelitis Optica Spectrum Disorders (NMOSD) at a National Reference Centre

P1.2

Upregulated complement receptors correlate with Fc gamma Shuhei Nishiyama, MD,PhD receptor 3A-positive natural killer cells (NK) and natural killer-T cells (NKT) in neuromyelitis optica spectrum disorder

P1.3

FDA Approved Treatments for Neuromyelitis Optica Spectrum Disorder in Clinical Practice: A Survey of Academic Neuroimmunologists

P1.4

Neuromyelitis Optica Spectrum Disorder with Aquaporin-4 Immunoglobulin G (AQP-4 IgG) Seropositivity and Normal Neuroradiological Findings

Chukwuma Emmanuel Nwaze, MBBS

P1.5

Safety And Effectiveness Of Eculizumab In Japanese Patients With Aquaporin-4 Antibody-positive Neuromyelitis Optica Spectrum Disorder: Interim Analysis Of A Postmarketing Surveillance Study

Ichiro Nakashima, MD, PhD

P1.6

Long-term Eculizumab In AQP4+ NMOSD: Relapse-risk Reduction And Safety In PREVENT And Its Completed Openlabel Extension

Achim Berthele

P1.7

A Phase 3 Efficacy And Safety Study Of Ravulizumab In Adult Patients With Neuromyelitis Optica Spectrum Disorder: Study Design And Methodology

Sean J. Pittock, MD

P1.8

Disease characteristics of seropositive neuromyelitis optica spectrum disorder in a Turkish cohort

P1.9

Cryoglobulinemia and Neuromyelitis optica: a case of progressive weakness and neurocognitive decline

P1.10

Nipocalimab’s Selective Targeting of FcRn and IgG Clearance Preserves Key Immune Functions

P1.11

Validation of MATCH Score: a Predictive Tool for Identification of Patients With Kelch-like Protein-11 Autoantibodies

M Bakri Hammami, MD

P1.12

Caveolae-Associated Protein (cavin)-4 autoantibodies in immune mediated rippling muscle disease

M Bakri Hammami, MD

P1.13

Anti-Neuronal Nuclear Antibody 3 Autoimmunity targets Dachshund homolog 1

Anastasia Zekeridou, MD, PhD

Presenter Chirag Sunil Lalwani

Samet Cam Aimalohi Esechie, MD, PhD Leona Ling, PhD

AAN.com/SCQuickLinks

13

JULY 15 - POSTER SESSION 1

Robert Sharkus, DO

JULY 15 - POSTER SESSION 1

POSTERS Poster No.

Title

P1.14

Examining the Differences in Biomarkers of Neuronal and Glial Injury Between Autoimmune Neurologic Disease Patients and Healthy Controls

P1.15

A Severe Case of Lupus Cerebritis

P1.16

A rapidly fatal case of anti-GFAP receptor encephalitis due to acute brain edema and herniation

Roua Kahila, MD

P1.17

Characterization of Retinal Nerve Fiber Layer Thickness in a Cohort with Glutamic Acid Decarboxylase 65 and Glycine Receptor Autoimmunity

Yoji Hoshina, MD

P1.18

Differential Diagnosis in the Management of CPI Immunotoxicity: Case Series of Etiologies not to Miss

Timothy Gregory, MD

P1.19

Double seronegative Myasthenia gravis due to Pembrolizumab use for Metastatic Endometrial Adenocarcinoma

Melinda Burnett, MD

P1.20

Giant cell arteritis of the superior mesenteric artery presenting with Wernicke encephalopathy from thiamine deficiency

P1.21

Stiff Person Syndrome Misdiagnosis: Clinical and Ancillary Testing Characteristics

P1.22

Characterization of cardiac bradyarrhythmia associated with Hannah Zhao-Fleming, MD, PhD LGI1-IgG autoimmune encephalitis

P1.23

Are Insulin Mimetics Protective Against Comorbidity in Patients With Neuro-Autoimmune Disease?

Mohsen Ahmed

P1.24

Do Those with Neuro-Autoimmune Disease Carry a Higher Burden of Disease?

Mohsen Ahmed

P1.25

“Obvious” indications for Neural antibody testing in Epilepsy or Seizures: The ONES checklist

P1.26

Application of APE2 and RITE2 Scores in a Stanford Cohort of Trevor Robert Rafferty, MD Autoimmune Encephalitis Patients

P1.27

Treatment Outcome of Autoimmune Associated Epilepsy (AAE) vs Acute Symptomatic Seizures in Autoimmune Encephalitis (ASSAE) – A Single Center Experience

P1.28

High Dose Cannabidiol (CBD) in the Treatment of New-Onset Refractory Status Epilepticus (NORSE)

P1.29

Spectrum of Brain MRI features in CASPR2 associated Autoimmune Encephalitis: a case report with parietal lobe involvement.

P1.30

Do Anti-Epileptic Drugs Increase High Risk Comorbidity Amongst Patients with Neuro-Autoimmune Disease?

Mohsen Ahmed

P1.31

Neuroinflammatory disease responsive to MEK-inhibitor

Vicky Chen, MD

P1.32

Protective association of HLA-DRB1*04 subtypes in neurodegenerative diseases implicates acetylated tau PHF6 sequences

14 #AANSC

Presenter Tyler Lee Borko, BA, EMT-IV

Christopher Szewczyk

Sarah Shapiro

Nicholas H. Chia, MBBS

Yiu-Chia Chang, MD

Ning Zhong, MD

Seyhmus Aydemir, MD Luis Guillermo Manrique, MD

Guo Luo

Information is accurate as of June 14, 2022, and is subject to change.

Poster No.

Title

P1.33

Real-World Resource Utilization and Productivity Loss among Patients with Myasthenia Gravis in Sweden: A Nationwide Population-based Study

P1.34

Anti-myelin Oligodendrocyte Glycoprotein AntibodyAssociated Disorder (MOGAD) in a Pediatric Patient with Rare Presentation of a Cerebellar Tumefactive Lesion

P1.35

WITHDRAWN

P1.36

MOGAD in the Mountain West: Epidemiology and Outcomes in Pediatric and Adult Patients at Two Large Academic Referral Centers

Melissa Ann Wright, MD

P1.37

COVID-19 Vaccine Associated Demyelination & Its Association with MOG Antibody

Sunderraj Netravathi, MD

P1.38

A case of recurrent cerebral cortical encephalitis in MOG antibody-associated disease

P1.39

Expanding The Radiological Spectrum of MOG Antibody Disease: Clues From an Observational Study

Kamakshi Dhamija, DM

P1.40

Development of new or enlarging MRI lesions outside of clinical attacks in MOG-antibody-associated disease

Stephanie Bridget SycMazurek, MD, PhD

P1.41

Recurrent Brainstem Lesions as a Manifestation of MOGAD Rumyar Vojdanian Ardakani,

P1.42

Spinal Central Canal Dilation in MOG Antibody-Associated Disease versus Other CNS Demyelinating Disorders

P1.43

Exposure to TNF inhibitors is rare at MOGAD diagnosis

P1.44

Neuroinvasive West Nile Virus Disease Presenting as Opsoclonus-Myoclonus-Ataxia Syndrome

P1.45

Etiology and Factors Related Outcomes of Longitudinally Extensive Transverse Myelitis in Thailand

P1.46

Characterization of Neurosarcoid Myelitis and Assessment of Treatment Response: A Multicenter Retrospective Study

P1.47

Resolution of Recurrent VZV Myelitis with the Use of Intravenous (IV) Immunoglobulin (IG)

P1.48

The Texas Children’s Hospital Experience with Pediatric anti- Alexander Sandweiss, MD, PhD NMDAR Encephalitis: 2010-2021

P1.49

Sjogren’s Sensory Neuropathy: A Potentially Treatable Condition with Early Intervention

Ryan Louis Naum, DO

P1.50

NMDA receptor encephalitis with severe orofacial dyskinesias treated with tramadol and clonazepam

Falen Fernandes, MD

P1.51

Predictors for the Development of Neurological Immunerelated Adverse Events of Immune Checkpoint Inhibitors and Impact on Mortality

P1.52

Do Aspirin and Other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Have a Protective Effect Against NeuroAutoimmune Disease and Comorbidity?

Presenter Qiaoyi Zhang, MD, PhD

Avni Sanghi, DO

Laura Cacciaguerra

Lauren Webb Vyanka Redenbaugh, MB BCh BAO Aditi Sharma, MBBS Nisa Vorasoot, MD Denis Tan Kerim Balaban, MD Danelvis Paredes, MD

Chen Yan, MD

Mohsen Ahmed

AAN.com/SCQuickLinks

15

JULY 15 - POSTER SESSION 1

MD

JULY 15 - POSTER SESSION 1

POSTERS Poster No.

Title

P1.53

Therapeutic Plasma Exchange in a Patient with Acute Motor Axonal Neuropathy Subtype of Guillain-Barre Syndrome and Systemic Lupus Erythematosus

P1.54

Neurochondrin Autoimmunity with Slow Saccades: A Case Report

P1.55

WITHDRAWN

P1.56

Refractory Pediatric NMDA Receptor Encephalitis: A Case Series

Varun Kannan, MD

P1.57

Clinical Improvement Following Delayed Initiation of Immunotherapy in a Case of LGI1 Antibody Encephalitis Presenting with Faciobrachial Dystonic Seizures Following COVID-19 Vaccination

Kayla Martin, MD

P1.58

Therapeutic Plasma Exchange in the Management of Stiff Person Syndrome Spectrum Disorders: A Case Series and Review of the Literature

Shuvro Roy, MD

P1.59

Clinical and paraclinical features of non-paraneoplastic NIFmediated disease associated with concurrent SARS-CoV-2 infection

Lauren Schmidt, MD

P1.60

Real-world Utilization Patterns of Intravenous Immunoglobulin in Adults with Generalized Myasthenia Gravis in the United States

Cynthia Zhengyun Qi

P1.61

Neurological Immune-Related Adverse Events After COVID-19 Vaccination: A Systematic Review

P1.62

Post COVID-19 vaccination associated acquired neuromyotonia

Shivangi Shivangi, MBBS

P1.63

PANDAS : A rare case amalgamation of infective, autoimmune and neuropsychiatric illness

Neelam Kumari Sahu, MD

P1.64

Medusa-head Antibodies—More than Cerebellar Ataxia: Report of Two Cases

P1.65

Testing for N-type Voltage Gated Calcium Channel Antibody has limited utility in evaluating patients with suspected Lambert-Eaton Myasthenic Syndrome

P1.66

Is COVID-19 Vaccination Associated with an Increased Reporting Rate of Myasthenic Crisis? A Vaccine Adverse Event Reporting System (VAERS) Study

Om Kothari

P1.67

A systematic review and quantitative synthesis of the long-term psychiatric sequelae of pediatric autoimmune encephalitis

Linda Nguyen, MD, PhD

P1.71

Autoimmune Encephalitis Misdiagnosis: A Review of Reported Cases

Maria Daniela Orellana Zambrano

P1.72

The Complicated Course of a Patient with Faciobrachial Dystonic Seizures Associated with LGI1-antibody Limbic Encephalitis

P1.73

Autoimmune Encephalitis—A Diagnostic Challenge For The Neurologist

16 #AANSC

Presenter Melissa Ann Huberman

Laurel Tanke

Ameena Shafiq

Lei Liu, MD, PhD Masoud Majed, MD

Dilasha Neupane, MD

Laxmi Khanna, MD, MBBS, SCE Neurol

Information is accurate as of June 14, 2022, and is subject to change.

Poster No.

Title

P1.74

Brains on Fire: Patient Outcomes and Quality of Life following Autoimmune Encephalitis

P1.75

Coexistance of Probable Neurosarcoidosis and Generalize Myasthenia Gravis: Case Report

P1.78

Evidence For and Against Subclinical Disease Activity and Progressive Disease in MOG Antibody Disease and Neuromyelitis Optica Spectrum Disorder

P1.80

Utilizing Efgartigimod on refractive Pembrolizumab-induced myasthenia gravis-like syndrome: A case report

P1.81

Are Neurological Manifestations a Predictor of Poor Prognosis in Patients with Neuro-Autoimmune Disease?

Afaaq Ahmed

P1.83

Cervical Spinal Cord Compression Due to Hypertrophic Pachymeningitis in a Patient with Ankylosing Spondylitis

Rajesh K. Gupta, MBBS

Presenter Ava Maria Easton, PhD Itziar Abad Michael Levy, MD, PhD, FAAN Maryellen Campbell

Poster No.

Title

P1.68

CAR-T cell-mediated B cell depletion in central nervous system autoimmunity

P1.69

A rare neuromyelitis optica mimic: Primary CNS histiocytic sarcoma

P1.70

Recurrent Foreign Body Reactions to Neuroendovascular Polymers – A Clinicopathologic Case Study

P1.76

Neuro-Behcet’s Disease Presenting as a Psuedotumoral Brainstem Mass: A Case Report

P1.77

Epidemiology and Burden of NMOSD, MS, and MOGAD in Thailand: a Population-based Study

P1.79

Acute Central Nervous System Demyelination Following COVID-19 Vaccination

P1.82

Spinal cord neurosarcoidosis: a clinical-radiological correlation of 39 cases

Presenter Sasha Gupta, MD Jamie C. McDonald, MD William Lou, MD Heather Yun Fei Yong, MD Nanthaya Tisavipat, MD Sydney Lee, MD Rami Al-Hader, MD

AAN.com/SCQuickLinks

17

JULY 15 - POSTER SESSION 1

MS and CNS Inflammatory Disease

Industry Therapeutic Update From argenx Innovation in Anti-AChR Antibody Positive gMG Treatment for Adults: Clinical Data of VYVGART in the Pivotal ADAPT Trial Join us for breakfast as we discuss the phase 3 pivotal trial data for FDA-approved VYVGART® (efgartigimod alfa-fcab). VYVGART offers a unique mechanism of action for treating anti-AChR antibody positive generalized myasthenia gravis (gMG) in adults. gMG is a rare but debilitating disease, whereby pathogenic immunoglobulin G (IgG) autoantibodies cause failure of signal transmission at the neuromuscular junction. The neonatal Fc receptor (FcRn) is a molecule that recycles IgG antibodies, including pathogenic autoantibodies, rescuing them from lysosomal degradation and perpetuating the underlying pathophysiology behind gMG. VYVGART is a human IgG1-derived Fc fragment that blocks FcRn and prevents IgG recycling, resulting in a reduction of circulating IgG, including levels of pathogenic autoantibodies that impair neuromuscular transmission in adult patients with gMG who are anti-AChR antibody positive. Join us and get your questions about VYVGART answered by our distinguished speakers.

INDICATION

VYVGART® (efgartigimod alfa-fcab) is indicated for the treatment of generalized myasthenia gravis in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.

IMPORTANT SAFETY INFORMATION WARNINGS AND PRECAUTIONS Infection VYVGART may increase the risk of infection. The most common infections observed in Study 1 were urinary tract infection (10% for VYVGART vs 5% for placebo) and respiratory tract infection (33% for VYVGART vs 29% for placebo). Patients on VYVGART vs placebo had below normal levels for white blood cell counts (12% vs 5%, respectively), lymphocyte counts (28% vs 19%, respectively), and neutrophil counts (13% vs 6%, respectively). The majority of infections and hematologic abnormalities were mild to moderate in severity. Delay VYVGART administration in patients with an active infection until the infection is resolved; monitor for clinical signs and symptoms of infections. If serious infection occurs, administer appropriate treatment and consider withholding VYVGART until the infection has resolved.

Immunization Immunization with vaccines during VYVGART treatment has not been studied; the safety with live or live-attenuated vaccines and the response to immunization with any vaccine are unknown. Because VYVGART causes a reduction in immunoglobulin G (IgG) levels, vaccination with live-attenuated or live vaccines is not recommended during VYVGART treatment. Evaluate the need to administer age-appropriate vaccines according to immunization guidelines before initiation of a new treatment cycle with VYVGART.

Please see Important Safety Information within and full Prescribing Information (PI) at VYVGART.com/PI. The full PI will also be available at the symposium.

This presentation is not part of the AAN Summer Conference Education or Scientific programs and is not endorsed by the AAN. This activity is not a CME program, nor will CME credit be given for attendance. argenx complies with all applicable laws, regulations, ordinances, and industry standards that relate tointeractions with health care professionals, including transparency disclosure requirements.

18 #AANSC

Session Faculty Ali A. Habib, MD

Associate Professor Director, EMG Laboratory MDA ALS & Neuromuscular Center University of California, Irvine

Srikanth Muppidi, MD

Clinical Associate Professor, Neurology and Neurological Sciences Stanford University

Antoine Azar, MD

Clinical Director, Division of Allergy and Clinical Immunology Director, Adult Primary Immunodeficiency Center Assistant Professor of Medicine Johns Hopkins University School of Medicine

Join Us! Saturday, July 16, 2022 6:30 am to 7:45 am (PDT)

Breakfast will be served Salon 4 / 5 San Francisco Marriott Marquis

Hypersensitivity Reactions Hypersensitivity reactions, including rash, angioedema, and dyspnea, were observed with VYVGART. In clinical trials, hypersensitivity reactions were mild or moderate, occurred within 1 hour to 3 weeks of administration, and did not lead to treatment discontinuation. Monitor patients during administration and for 1 hour thereafter for clinical signs and symptoms of hypersensitivity reactions. If a hypersensitivity reaction occurs during administration, discontinue VYVGART infusion and institute appropriate supportive measures if needed.

ADVERSE REACTIONS The most common (≥10%) adverse reactions with VYVGART were respiratory tract infection, headache, and urinary tract infection.

USE IN SPECIFIC POPULATIONS Pregnancy As VYVGART is expected to reduce maternal IgG antibody levels, reduction in passive protection to the newborn is anticipated. Risk and benefits should be considered prior to administering live or live-attenuated vaccines to infants exposed to VYVGART in utero.

Lactation There is no information regarding the presence of VYVGART in human milk, the effects on the breastfed infant, or the effects on milk production.

The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for VYVGART and any potential adverse effects on the breastfed infant from VYVGART or from the underlying maternal condition.

Please see the full Prescribing Information.

You may report side effects to the US Food and Drug Administration by visiting http://www.fda.gov/medwatch or calling 1-800-FDA-1088. You may also report side effects to argenx US, Inc, at 1-833-argx411 (1-833-274-9411).

©2022 argenx, US, Inc MED-US-VYV-2200020 v1.0 June 2022

AAN.com/SCQuickLinks

19

POSTERS

JULY 16 - POSTER SESSION 2

Autoimmune Neurology Poster No.

Title

P2.1

Serum Autoantibody Lowering by the Anti-FcRn Monoclonal Antibody, Nipocalimab, Correlates with Clinical Improvement in Generalized Myasthenia Gravis Patients

P2.2

Long-term Safety and Efficacy of Efgartigimod in Patients With Generalized Myasthenia Gravis: Interim Results of the ADAPT+ Study

P2.3

Numbers Needed to Treat and Costs Per Improved Outcome Among Treatments for Myasthenia Gravis

P2.4

The ExTINGUISH Trial: A Phase-2B randomized placebocontrolled trial of inebilizumab in anti-NMDA receptor encephalitis

P2.5

Safety, Efficacy, And Pharmacokinetics Of Argx-117 In Adults With Multifocal Motor Neuropathy: A Global, Multicenter, Placebo Controlled Phase 2 Study (Arda)

P2.6

Vibrance-mg: Clinical Trial of Nipocalimab in Pediatric Myasthenia Gravis

Judith Profant

P2.7

Vivacity MG Phase 3 Study: Clinical Trial of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis

Judith Profant

P2.8

Response of Sjogren-related Small Fiber Neuropathy to rituximab

P2.9

The First Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Efficacy and Safety of an FcRn Inhibitor, Rozanolixizumab, in Patients with Leucine-rich Glioma-inactivated 1 Autoimmune Encephalitis

P2.10

Do Statins Have a Protective Effect Against NeuroAutoimmune Disease and Comorbidity?

P2.11

Clinical experience with efgartigimod in generalized myasthenia gravis: results from a case series of US-based patients participating in an Expanded Access Program

P2.12

Steroid Un-Responsive Encephalopathy Associated with Autoimmune Thyroiditis (SUEAT) in Pediatric Patients

Geetanjali Singg Rathore, MD

P2.13

The Role of Plasmapheresis In Pediatric Antibody- Negative Autoimmune Encephalitis

Geetanjali Singg Rathore, MD

P2.14

First Case Report of AMPA Receptor Encephalitis Presenting with Features of Parkinsonism

Chirag Sunil Lalwani

P2.15

Observational Study of Spectrum of Serological, Clinical and Radiological Profile of 38 Autoimmune Encephalitis Patients

Raghav Kapoor, Sr., MD, MBBS

P2.16

Rapidly Progressive Dementia with Recurrent Seizures and Hyponatremia; A Case of LGI1 Limbic Encephalitis

P2.17

Co-Occurrence of Sj/ITPR1 and NMDA Antibodies: A Case Report

20 #AANSC

Presenter Leona Ling, PhD

Edward Brauer

Tom Hughes, PhD Ka-Ho Wong

Jeffrey Aaron Allen

Anita Nandini Venkatesh, MD Divyanshu Dubey, MD

Mohsen Ahmed Deborah Gelinas, MD

Ashley Barasa, MD William Daniel Chapman, DO

Information is accurate as of June 14, 2022, and is subject to change.

Poster No.

Title

P2.18

Expanding frontiers in autoimmune encephalitis

P2.19

Autoimmune Encephalitis: Modifiable and Non-modifiable Predictors of Relapse

P2.20

Concurrent Autoimmune Encephalitis, Diabetes, and Thyroiditis after a single dose of Pembrolizumab.

P2.21

An Atypical Case of GFAP Astrocytopathy

P2.22

Autoimmune Encephalitis with Ganglionic a3-AChR Antibodies

Ghaida Khalaf Zaid, MD

P2.23

Autistic regression Sequelae or Relapse for NMDA Receptor Antibody Encephalitis

Ghaida Khalaf Zaid, MD

P2.24

CSF Indices in Autoimmune Encephalitis: Promising Predictors of Treatment Response

Ekaterina Yuryevna Popova

P2.25

Recurrent Acute Necrotizing Encephalopathy with underlying RANBP2 mutation

Dhanalakshmi Angappan, MD

P2.26

Primary Immune Dysregulation in Subacute Sclerosing Panencephalitis: A Case-Control Study

P2.27

Rank wise effect of HLA-DQ5 explains risk for the development of anti-IgLON5 disease

P2.28

Genetics of anti-NMDAR encephalitis

P2.29

Cohort Study of Autoimmune Encephalitis(AIE) in Pediatric and Adult Population from India-A Single Tertiary Centre Experience

P2.30

Long-Term Psychiatric Symptoms in Autoimmune Encephalitis Remission

P2.31

The Clinical Response of California Serogroup Virus Neuroinvasive Disease in a Pediatric Patient to Intravenous Immunoglobulin (IVIG) Therapy

Avni Sanghi, DO

P2.32

Expanding Our Knowledge Of The Immunogenetic Characteristics Of Anti-LGI1 Encephalitis – A Study Of An Israeli Cohort Suggests Additional Significant HLA Associations With DQ Alleles

Yahel Segal, MD

P2.33

Anti-AMPAR encephalitis presenting as cerebritis and rhombencephalitis in a pediatric patient

Hannah Oppenheim, MD

P2.34

Broadening the Differential of Autoimmune Encephalitis: Diagnostic and Therapeutic Considerations in Down Syndrome Disintegrative Disorder

P2.35

Understanding Correlation of Electroclinical Findings with Functional and Neuropsychiatric Outcomes in Patients with LGI1-Encephalitis

P2.36

An Observational Study on the Humoral and Cellular Immune Tyler Lee Borko, BA, EMT-IV Response to SARS-CoV-2 mRNA Vaccination in Multiple Sclerosis and Other Autoimmune Neurological Disorders treated with Anti-CD20 Therapies

Presenter Habib Georges Moutran Barroso, MD Megan A Hansen, MD Ali AlMoamen, MB BCh BAO Maxime Junior Jean, MD, PhD

Selina Yogeshwar, MSc Sara Lomba Nagashree Sharma, Jr., MD

Ramy Sameh Gabarin

Aisha Elfasi, MD

Carol Swetlik, MD

AAN.com/SCQuickLinks

21

JULY 16 - POSTER SESSION 2

Vinay Suresh

JULY 16 - POSTER SESSION 2

POSTERS Poster No.

Title

P2.37

Creation and Implementation of a Multi-Disciplinary Clinical Workflow Aimed at Earlier Diagnostic Evaluation for Autoimmune Encephalitis for Patients Presenting with Atypical Psychosis: A Pilot Study

P2.38

Two Cases of Isolated Neurofilament Heavy Chain Antibody Syndrome

P2.39

False Positive Cerebrospinal Fluid NMDA Receptor Antibodies: A Single Center Case Series

P2.40

Treatment-Refractory Autoimmune Glial Fibrillary Acidic Protein Meningoencephalomyelitis in a Young Adult Female

P2.41

Autoimmune Encephalitis Misdiagnosis in Adults; a multicenter observational study of outpatient subspecialty clinics

P2.42

Glial Fibrillary Acidic Protein (GFAP) Antibody-associated Astrocytopathy in Systemic Sarcoidosis

Elizabeth Matthews, MD

P2.43

Autoimmune Encephalitis – “Review of Cases with Diverse Presentations”

Amaravathi Markala, Sr., MD

P2.44

Case of Anti-NMDA Receptor Encephalitis Presenting in a Toddler with Hemorrhagic Cavernomas

P2.45

Anti- DPPX antibody encephalitis with a pan-positive review of systems

Mustafa Ridvan Donmez, MBBS

P2.46

Acute Autoimmune Encephalitis with Features of Bickerstaff Brainstem Encephalitis (BBE) and Two Abnormal Autoantibodies Presenting with Prominent Cerebellar Abnormality on MRI– a Case Report

Osman Ozel, MD

P2.47

Active Immunization Against NMDA NR1 Subunit as a Model of Autoimmune Encephalitis

Grace Jachimiec

P2.48

A retrospective analysis of relapse rate in pediatric and adult autoimmune encephalitis

Linda Nguyen, MD, PhD

P2.49

WITHDRAWN

P2.50

A Case of Bilateral Sequential Optic Neuropathies with Pachymeningitis and Aortitis: Difficulty in Differentiating Erdheim-Chester Disease from IgG4-Related Disease.

P2.51

Clinical Characteristics of Double SeroPositive Myasthenia Gravis

P2.52

WITHDRAWN

P2.53

The Eye as a Window to the Brain: Prominent Retinal Vasculopathy Points to Neuro-Behcet Diagnosis for an Undifferentiated Solitary Brain Lesion

P2.54

A Case of Recurrent Idiopathic Hypertrophic Pachymeningitis after Years of Quiescence

P2.55

Unmasking of a Relapsing Encephalomyelitis after SARSCoV-2 Infection and COVID-19 Vaccination

P2.56

WITHDRAWN

22 #AANSC

Presenter Grace Brady Russo, MD

Alex Mirzoev, MD Rumyar Vojdanian Ardakani, MD Janetta Lorenza Arellano, MD Michael D. Geschwind, MD, PhD, FAAN

Kayla Jacques, MD

Tefani Perera, MD

Hamsini Movva, MBBS

Sonam Dilwali, MD, PhD

Benjamin Bird, MD Shuvro Roy, MD

Information is accurate as of June 14, 2022, and is subject to change.

Poster No.

Title

P2.57

Characteristics and Evolution of Cerebral Aneurysms Among Adults Living with HIV: A Retrospective, Longitudinal Case Series

P2.58

Headache As Initial Presentation of Human Chronic Necrotizing Granulomatous Meningoencephalitis

P2.59

Ischemic Stroke in Neurosarcoidosis: a Retrospective Cohort Analysis

P2.60

Pachymeningitis in Biopsy-proven Sarcoidosis: Clinical Course, Radiographic Findings, Response to Treatment, and Long-term Outcomes

P2.61

Case Review of Alternative Treatment in Patient with Immunotherapy Induced Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Melissa Ann Huberman

P2.62

MS and Sarcoidosis: a Case Series for Coexistence

Scott M. Belliston, DO

P2.63

Unanticipated Improvement of Stiff Person Syndrome after Severe COVID-19 infection: A case report.

P2.64

Opsoclonus Myoclonus Syndrome and Supraventricular Tachycardia in a Pediatric Patient: A Case Report and Literature Review

ENCEPHALITIS C O N F E R E N C E

Presenter Emily I. White, MD

Khaled Gharaibeh, MD Spencer Hutto, MD Pressley A. Chakales, MD

Toluwalase Oluwakemi Tofade, MBBS John Zachary Korin

ENCEPHALITIS 2022 30TH NOVEMBER & 1ST DECEMBER 2022 ROYAL COLLEGE OF PHYSICIANS, LONDON, UK AND VIRTUALLY

KEYNOTE SPEAKERS

Assoc Prof Stacey L Clardy, University of Utah and Salt Lake City VA, USA Prof Russell Dale, University of Sydney and The Children’s Hospital at Westmead, Australia

Become a member of the Encephalitis Society (membership is free) to access a wide range of benefits: research grants and bursaries, priority access and discount rates to our annual Encephalitis Conference and other events, networking and development opportunities, support for your patients.

www.encephalitis.info/ professional-membership

GUEST SPEAKERS

Prof Tom Solomon CBE, University of Liverpool and Brain Infections Group, UK Dr Julia Granerod, Epidemiologist, Independent Consultant, UK

KEYNOTE/GUEST SPEAKER TOPICS: DEXENCEPH study, Autoimmune encephalitis trials, Paediatric encephalitis, Global impact of encephalitis DEBATE: Chaired by Prof Sarosh Irani, University of Oxford, UK “This house believes that too many patients with psychiatric illness are being unhelpfully diagnosed with brain autoimmunity”

BOOK YOUR PLACE NOW

www.encephalitis.info/encephalitis-2022 AAN.com/SCQuickLinks 23

JULY 16 - POSTER SESSION 2

POSTERS Poster No.

Title

P2.65

GABABR IgG associated encephalitis: Clinical presentations and measures to improve diagnostic assay specificity

P2.66

A Case of Paraneoplastic NMOSD with Sarcoma and Unusual Cauda Equina Enhancement

P2.67

Missed Opportunities to Prevent N-methyl-D-aspartate Receptor (NMDAR) Encephalitis in a DREAMer

P2.68

Neuronal Uptake of Paraneoplastic and Other IgGs is Mediated by the Fc Portion of the IgG Molecule and Involves Previously Uncharacterized Neuronal FcyRI Receptors: Implications for Antibody-Mediated Neuronal Injury

Tammy L. Smith, MD, PhD

P2.69

Anti-Tr/DNER Paraneoplastic Cerebellar Degeneration with Marked Cerebellar and Psychological Symptoms Responsive to Plasma Exchange

Paul Daniel Crane, MD

P2.70

CASPR-2 Antibody Associated Autoimmunity in the Setting of COVID-19 (Infection, Vaccination, or Both?) and Chronic Lymphocytic Leukemia: Case Report and Review of the Literature

P2.71

A Woman With Kelch-like Protein-11 Encephalitis and Unmasked Metastatic Carcinoma

P2.72

A Case of Pembrolizumab (Anti-PD-1) Induced Encephalitis

P2.76

Co-Occurring NMDA-Receptor and anti-GAD65 Antibodies in the CSF of a Patient with Encephalitis: Case Report

P2.84

Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) as a novel presentation of CNS autoimmunity in a pediatric patient with Wiskott-Aldrich syndrome (WAS)

Presenter Jennifer McCombe, MD Mohammed Hussein, MD Paul Daniel Crane, MD

Neda Sattarnezhad, MD

Paunel Agyei, MD Anza Zahid, MD, MBBS Caleb Richard Schatz McEntire, MD Vivien Xie, MD

Autonomic Disorders Poster No.

Title

P2.73

Immunotherapy with subcutaneous immunoglobulin or plasmapheresis in patients with Postural Orthostatic Tachycardia Syndrome (POTS)

Presenter Renee Nelson

Child Neurology and Developmental Neurology Poster No.

Title

P2.74

Role of Immunotherapy in Down Syndrome Disintegrative Disorder (DSDD)

24 #AANSC

Presenter Nidhiben A. Anadani, MD

Information is accurate as of June 14, 2022, and is subject to change.

Epilepsy/Clinical Neurophysiology (EEG) Poster No.

Title

P2.75

EEG Characteristics in Hospitalized Patients with Acute COVID-19 Symptoms

Presenter Ganesh Murthy, MD

Infectious Disease Poster No.

Title

P2.78

Progressive Multifocal Leukoencephalopathy Associated With Sarcoidosis: A Multi-Center Case Series

P2.79

“Trigeminal Tract Sign” in Patients with Herpes Zoster Ophthalmicus: A Case Series of a Novel Imaging Finding

Presenter Caleb Richard Schatz McEntire, MD Heather Yun Fei Yong, MD

Poster No.

Title

P2.77

Neuroblastoma Presentation with Multiple Cranial Nerve Involvement

Presenter Aysha Arshad

Neuromuscular and Clinical Neurophysiology (EMG) Poster No.

Title

P2.80

Characterization of Clinical and Paraclinical Features Associated with TS-HDS Autoantibody Seropositivity

P2.81

BNT162b2 mRNA COVID-19 Vaccine Three-Dose Safety and Risk of COVID-19 in Patients with Myasthenia Gravis

Alon Doron

P2.82

Comparison of Fixed Cell-based Assay to Radioimmunoprecipitation Assay for Acetylcholine Receptor Antibody Detection in Myasthenia Gravis

Ario Mirian, MD

Presenter Mohamed Mostafa Rezk, MD

Research Methodology and Education Poster No.

Title

P2.83

Piloting an Advanced Neuroimmunology Elective for Neurology Residents

Presenter Sonia Kaur Singh, MD

AAN.com/SCQuickLinks

25

JULY 16 - POSTER SESSION 2

Neuro-oncology

ob ill D

13 12 11 10 9 8 7 6 5 4 3 2 1

14 15 16 17 18 19 20 21 22 23 24

Yerba Buena Ballroom Foyer Nob Hill C

Nob Hill B

26 #AANSC

Nob Hill A

Assembly

EXHIBIT HALL

Exhibit Hall Passport Destination

12 Alexion Pharmaceuticals

19 argenx

alexion.com

argenx.com

Alexion is a global biopharmaceutical company with the mission of transforming the lives of people affected by rare diseases by continuously innovating and creating meaningful value in all that we do.

Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.

argenx is a global immunology company developing antibody-based medicines for patients suffering from severe autoimmune diseases and cancer. By translating immunology breakthroughs into innovative drug candidates, argenx is building a worldclass portfolio of first-in-class antibodies in both early and late clinical-stages of development.

21 American Telephysicians americantelephysicians.com American TelePhysicians is physicianled digital healthcare and telemedicine company with expertise in building 360º healthcare ecosystems. We have launched projects in Asia, Australia, Africa, and North America, and we continue to expand in new markets with a focus on improving healthcare access by utilizing technology and innovation.

22 argenx argenx.com argenx is a global immunology company developing antibody-based medicines for patients suffering from severe autoimmune diseases and cancer. By translating immunology breakthroughs into innovative drug candidates, argenx is building a worldclass portfolio of first-in-class antibodies in both early and late clinical-stages of development.

15 Amylyx Pharmaceuticals amylyx.com Amylyx is a biopharmaceutical company with the mission to develop therapies for neurodegenerative diseases. With offices in Cambridge, Massachusetts; Canada; and Amsterdam, NL, Amylyx collaborates with people living with neurodegenerative diseases and their caregivers, industry leaders, scientists, doctors, and research organizations to make a positive impact.

For more information, visit www.amylyx. com and follow us on LinkedIn and Twitter.

AAN.com/SCQuickLinks

27

EXHIBITORS 8 Banner Life Sciences

10 Cala Health

bannerls.com/en/

calahealth.com

Banner Life Sciences is committed to advancing human health through scientific innovation. We are a uniquely innovative and entrepreneurial specialty pharmaceutical company. We identify unmet clinical needs for patients, and then leverage our proprietary formulation expertise and technologies to create unique solutions that not only help people to live healthy, happy lives, but also offer significant commercial advantages and valuable IP protection. Our in-house capabilities cover all the essential new product functions such as product development, clinical research, and regulatory affairs, and commercialization so we’re able to execute an end-to-end, turnkey process for creating exciting new products.

The company’s first to market wrist-worn neuromodulation device, Cala Trio™ therapy, delivers electrical stimulation from the affected hand to the brain providing meaningful, temporary tremor reduction.

Cala Trio therapy is delivered in 40-minute sessions calibrated to each patient’s individual tremor. Patients choose when and how often they will utilize therapy.

Cala Trio therapy is noninvasive, FDA cleared, safe and effective and available only through a healthcare providers prescription.

9 Baylor Scott & White Healthcare bswhealth.com Baylor Scott & White Health is transforming healthcare for the Better, so that our patients and health plan members receive the high-value care they deserve when and where they need it. Our team of over 47,000 employees across more than 1,000 access points is committed to the well-being of every individual, family and community we serve. Through innovation, education and care delivery, we strive to provide an exceptional customer experience, while working to make healthcare more convenient and more affordable.

28 #AANSC

24 Catalyst Pharmaceuticals catalystpharma.com Catalyst Pharmaceuticals is a commercialstage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel highquality medicines for patients living with rare diseases. With exceptional patient focus, Catalyst is committed to developing a robust pipeline of cutting-edge, first- or best-in-class medicines for other rare diseases. To learn more, please visit our website at www.catalystpharma.com.

Information is accurate as of June 14, 2022, and is subject to change.

Exhibit Hall Passport Destination

2 Genentech

7 Horizon Therapeutics

gene.com

horizontherapeutics.com

Considered the founder of the industry, Genentech, now a member of the Roche Group, has been delivering on the promise of biotechnology for over 35 years. At Genentech, we use human genetic information to discover, develop, manufacture and commercialize medicines to treat patients with serious or lifethreatening medical conditions. Today, we are among the world’s leading biotech companies, with multiple products on the market and a promising development pipeline.

Horizon is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases.

Our pipeline is purposeful: we apply scientific expertise and courage to bring clinically meaningful therapies to patients.

We believe science and compassion must work together to transform lives.

13 Kyowa Kirin kyowakirin.com

23 Genentech gene.com Considered the founder of the industry, Genentech, now a member of the Roche Group, has been delivering on the promise of biotechnology for over 35 years. At Genentech, we use human genetic information to discover, develop, manufacture and commercialize medicines to treat patients with serious or lifethreatening medical conditions. Today, we are among the world’s leading biotech companies, with multiple products on the market and a promising development pipeline.

Kyowa Kirin is a global specialty pharmaceutical company with US Headquarters based in Princeton, NJ. The company is focused primarily on developing and commercializing biopharmaceuticals that help improve the health and wellbeing of people through innovative and state-of-the-art technologies in various therapeutic areas including oncology, neurology, nephrology, and immunology.

You can learn more about our values, our business and how we help patients facing serious illnesses, like Parkinson’s disease, by visiting https://kkna.kyowakirin.com/.

AAN.com/SCQuickLinks

29

EXHIBITORS 16 Mayo Clinic

20 McKesson

mayoclinic.org/medical-professionals/ neurology-neurosurgery

mckesson.com/neurology

Mayo Clinic’s multidisciplinary teams diagnose and treat more than 500 neurological conditions, including many rare or complex disorders, for more than 100,000 patients every year.

Mayo offers access to state-of-theart diagnostic and treatment facilities and numerous groundbreaking clinical trials. A multispecialty team and Mayo Clinic’s clinical expertise drives strong collaboration with referring physicians throughout their patient’s care. Visit Mayo Clinic at Booth 16 to learn more.

17/18 Mayo Clinic Laboratories When you choose Mayo Clinic Laboratories for your patients’ neurological testing needs, you gain insights and guidance from a world-renowned hospital with more than 150 years of diagnostic experience.

Our robust neurology testing menu, including more than 400 highly specialized evaluations, allows you to consolidate more of your sendout testing to one trusted lab. We see thousands of patients every day—some with the most rare and complex cases—and continually innovate to develop new testing approaches that enable answers on the simplest to most complicated neurological conditions. In addition, due to the growing recognition of the prevalence of autoimmune neurological conditions in children, we offer a comprehensive pediatric autoimmune evaluation—the only one of its kind.

30 #AANSC

McKesson provides neurologists the freedom to focus on care through solutions and services such as the Onmark® GPO, Lynx® for inventory management, managed care and revenue cycle advisors, and Intrafusion® infusion management. For more information, visit www.mckesson.com/neurology.

4 National MS Society nationalmssociety.org/ForProfessionals The National MS Society exists because there are people with multiple sclerosis.

Our vision is a world free of MS. Everything we do is focused so that people affected

by MS can live their best lives as we stop MS in its tracks, restore what has been lost and end MS forever. The Society provides information and resources for clinicians, including continuing education programs, clinical and research funding opportunities, materials on diagnosing and managing MS, resources for your patients, and much more. To learn more and see what we offer, visit us at: www.nationalmssociety.org/ForProfessionals.

Information is accurate as of June 14, 2022, and is subject to change.

Exhibit Hall Passport Destination

14 Novartis Pharmaceuticals

5 Piedmont Healthcare

novartis.com

Piedmont.org/practicewithus

Novartis is reimagining medicine to improve and extend people’s lives. We use innovative science and digital technologies to create transformative treatments.

Novartis products reach more than 750 million people globally and we are finding innovative ways to expand access to our medicines. About 105,000 people of more than 140 nationalities work at Novartis. www.novartis.com.

Piedmont Healthcare is a top-rated system with award winning hospitals and employees comprised of over 16 hospitals, more than 2,500 physicians, and over 700 clinic practice locations across greater Atlanta and North Georgia. With over 1 million outpatient encounters, you will have the opportunity to see and treat a variety of medical conditions. Metro Atlanta’s vibrant economy fuels a wealth of global communities and diverse cultural experiences, while the state of Georgia offers coastline beaches and mountain views. Live and work with the best at Piedmont in the big and small towns of the Peach State.

3 PatientPoint patientpoint.com PatientPoint® is the patient engagement platform more providers trust. From patient acquisition to in-office and hospital engagement to remote care, our innovative, tech-enabled solutions deliver highly relevant, personalized health experiences across the entire patient journey. More than 140k healthcare providers and 500 hospitals trust PatientPoint to help them increase practice efficiencies, enhance the patient experience and improve outcomes.

See how we can do the same for you. Learn more at patientpoint.com.

6 Quest Diagnostics questdiagnostics.com/home Quest Diagnostics empowers people to take action to improve health outcomes.

Derived from the world’s largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors, and improve health care management. We serve half of the physicians and hospitals in the United States.

AAN.com/SCQuickLinks

31

EXHIBITORS 11 Sanford Health sanfordhealth.org Sanford Health is the largest rural notfor-profit health care system in the nation and is dedicated to excellence in patient care, innovation and pioneering integrated care. Our model of integrated health provides care through physicians, hospitals, health plan, research and education. Our reputation of excellence is founded on our talented team of more than 28,000 employees and over 1,400 primary and specialty care physicians located in 140 locations throughout Iowa, Minnesota, Montana, Nebraska, North Dakota, and South Dakota.

1 Sutter Health sutterhealth.org/physician-opportunities Sutter Health, Sacramento Sierra Region serves Sacramento, Placer, Yolo, Solano, Yuba, and Sutter counties. We strive to provide access to PCPs and specialty services in each of our communities and have a network of over 1,000 physicians locally and nearly 5,000 throughout the SH System. We are one of the nation’s leading community-based, not-for-profit healthcare networks of hospitals, physician organizations, home health, and hospice agencies, and other healthcare services.

They are situated near major West Coast attractions: San Francisco, Sacramento, Lake Tahoe, Napa Valley, Yosemite Valley, and the coastal redwoods. Join us and be part of a dedicated group of professionals with the resources, training, and expertise to provide the most advanced and highest quality health care.

32 #AANSC

Information is accurate as of June 14, 2022, and is subject to change.

CHELSEY LIVING WITH NMOSD

Rare Inspiration.

Changing Lives.

At Alexion, our mission is to transform the lives of people affected by rare diseases and devastating conditions through the development and delivery of innovative medicines, as well as through supportive technologies and healthcare services.

We believe it is our responsibility to listen to, understand, and change the lives of patients and those who work tirelessly to help them. Our passion drives us to continuously innovate and create meaningful value in all we do. In doing so, we change lives for the better – ours, people affected by rare diseases and devastating conditions, and the communities we serve. Every day. alexion.com

COVID-19 PROTOCOLS Visit AAN.com/SummerConference for complete information on our COVID-19 safety protocols.

Following are highlights and reminders for how we’re working to keep everyone safe.

Indicate Your Contact Comfort Level Choose a green, yellow, or red lanyard to communicate your comfort level: High fives and handshakes are okay with frequent hand washing.

Yellow: Elbows only. Still being cautious.

Red: No contact. Maintain distance where possible.

Green:

TThe AAN expects all attendees to be respectful of fellow attendees’ preferences.

Masks Strongly Encouraged Masks are strongly encouraged, but not required during the meeting. A limited supply of KN95 masks will be available near registration.

COVID-19 Testing Information about COVID-19 testing locations by appointment or walk-in is available on the city of San Francisco’s website (sf.gov/find-out-about-your-covid-19-testing-options).

34 #AANSC

CONFERENCE GUIDELINES & POLICIES The following are a selection of guidelines for AAN conferences. Complete conference guidelines are available at AAN.com/ConfGuidelines. AAN Summer Conference registrants must agree to conference guidelines during the registration process.

Unless specified, these guidelines apply to all AAN conference formats. In addition to the below guidelines, participation in a live or virtual AAN meeting is subject to AAN’s Privacy Policy (AAN.com/PrivacyPolicy). All individuals engaged in any live or virtual meeting are subject to the Code of Conduct at AAN.com/Conduct, unless otherwise specifically noted. Use of the website and virtual program site(s) is subject to AAN’s Terms of Use (AAN.com/TermsofUse).

These conference policies are subject to change without notice, at AAN’s discretion. Any changes will be reflected on AAN.com.

Accreditation ACCME Accreditation The American Academy of Neurology Institute (AANI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The AANI holds Accreditation with Commendation, the ACCME highest level of recognition for a CME provider. View the CME Mission Statement at AAN.com/CMEstatement.

AMA Credit Designation The AANI designates this live activity for a maximum of (*) AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. *See individual program descriptions starting on page 3 for the maximum number of credits per program.

ABPN Statement The American Board of Psychiatry and Neurology has reviewed the relevant AAN conference and has approved the program as a part of a comprehensive lifelong learning program, which is mandated by the ABMS as a necessary component of continuing certification.

AAN.com/SCQuickLinks

35

Select Meeting Policies Commitment to Inclusion, Diversity, Equity, Anti-racism, and Social Justice (IDEAS) The AAN is committed to intentional actions to be a fully inclusive, deliberately diverse, and anti-racist organization that respects and values our membership, our staff, and the communities we serve. We actively promote equity and social justice in neurology and the neurosciences. As part of this commitment, the AAN is working to ensure we provide a conference environment and educational programming that is fully inclusive, deliberately diverse, and anti-racist. If you have questions about these efforts, identify areas for improvement, or have concerns regarding attendee or staff behavior, please contact Member Services at (800) 879-1960, memberservices@aan.com, or conference staff at registration@aan.com.

Professional Conduct and Anti-harassment The AAN expects all meeting participants, including attendees, members, speakers, staff, contractors, vendors, and exhibitors, to behave respectfully, responsibly, and professionally towards each other, and to abide by the AAN’s Meetings Anti-harassment Policy (AAN.com/Anti-harassment), during the conference. The AAN is committed to providing a conference environment that is free from all forms of discrimination and harassment. Violations of this policy may be reported to Member Services at (800) 8791960, memberservices@aan.com, or to conference staff at registration@aan.com.

Social Media The American Academy of Neurology (AAN) encourages all AAN conference attendees to share their experience on social media using the official conference hashtag, #AANSC. When doing so, please adhere to the following AAN Meetings Social Media Policies: • Photography and screenshots of presentations are permitted for personal use only.

Photography or screenshots for commercial use are strictly prohibited.

• Do not disrupt fellow attendees.

• Do not post any information or other material protected by copyright without the permission of the copyright owner.

• Do not post confidential or identifiable patient information.

• Do not post any material that is defamatory, abusive, profane, threatening, offensive, illegal, or violates any third party’s rights.

• Videography, including live streaming, is strictly prohibited regardless of intended use.

• Usage of the AAN logo or an AAN conference logo on social media is prohibited.

The AAN has the right to ask any AAN conference attendee to remove a social post or to stop taking photos or recording video at any time.

36 #AANSC

UPGRADE YOUR REGISTRATION TO

GOLD

Get the best value – with extended access to session recordings, program materials, and ability to claim CME through May 30, 2023, when you upgrade your registration to Gold.

Upgrade to gold at registration or by emailing aanscsupport@cmrus.com.

The deadline to upgrade is August 15, 2022.

Note: Summer Conference On Demand will not include posters presented in San Francisco.

Student Member, Senior, or Honorary Member

Add $110

Intern or Junior Member

Add $110

Non-physician Member*

Add $200

Neurologist or Physician Affiliate Member

Add $300

Nonmember

Add $510

*Non-physician member includes Business Administrator, Researcher, and Advanced Practice Provider member types.

Upcoming Events!

October 28–30, 2022 Las Vegas April 22–27, 2023 Boston

July 28–29, 2023 Minneapolis

AAN.com/SummerConference • #AANSC